ID: ALA8562

Max Phase: Preclinical

Molecular Formula: C19H26O3

Molecular Weight: 302.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)c1cc(/C=C2\CCOC2=O)cc(C(C)(C)C)c1O

Standard InChI:  InChI=1S/C19H26O3/c1-18(2,3)14-10-12(9-13-7-8-22-17(13)21)11-15(16(14)20)19(4,5)6/h9-11,20H,7-8H2,1-6H3/b13-9+

Standard InChI Key:  DFPYHQJPGCODSB-UKTHLTGXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 302.41

Molecular Weight (Monoisotopic): 302.1882

AlogP: 4.32

#Rotatable Bonds: 1

Polar Surface Area: 46.53

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.63

CX Basic pKa:

CX LogP: 5.22

CX LogD: 5.22

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.62

Np Likeness Score: 0.52

References

1. Lazer ES, Wong HC, Possanza GJ, Graham AG, Farina PR..  (1989)  Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols.,  32  (1): [PMID:2491889] [10.1021/jm00121a021]

2. Mullican MD, Wilson MW, Connor DT, Kostlan CR, Schrier DJ, Dyer RD..  (1993)  Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents.,  36  (8): [PMID:8478906] [10.1021/jm00060a017]

3. Aizawa Y, Kanai T, Hasegawa K, Yamaguchi T, Iizuka Y, Iwaoka T, Yoshioka T..  (1990)  Studies on hindered phenols and analogues. 2. 1,3-Benzoxathioles having SRS-A inhibiting activity.,  33  (5): [PMID:2329571] [10.1021/jm00167a032]

4. Unangst PC, Connor DT, Cetenko WA, Sorenson RJ, Sircar JC, Wright CD, Schrier DJ, Dyer RD.  (1993)  Oxazole, thiazole, and imidazole derivatives of 2,6-di-tert-butylphenol as dual 5-lipoxygenase and cyclooxygenase inhibitors,  3  (8): [10.1016/S0960-894X(00)80051-7]

5. Lazer ES, Wong HC, Wegner CD, Graham AG, Farina PR..  (1990)  Effect of structure on potency and selectivity in 2,6-disubstituted 4-(2-arylethenyl)phenol lipoxygenase inhibitors.,  33  (7): [PMID:2113949] [10.1021/jm00169a010]

6. Malleron JL, Roussel G, Gueremy G, Ponsinet G, Robin JL, Terlain B, Tissieres JM..  (1990)  Penta- and hexadienoic acid derivatives: a novel series of 5-lipoxygenase inhibitors.,  33  (10): [PMID:2213827] [10.1021/jm00172a010]

7. Unangst PC, Connor DT, Cetenko WA, Sorenson RJ, Kostlan CR, Sircar JC, Wright CD, Schrier DJ, Dyer RD..  (1994)  Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity.,  37  (2): [PMID:8295221] [10.1021/jm00028a017]

8. Flynn DL, Belliotti TR, Boctor AM, Connor DT, Kostlan CR, Nies DE, Ortwine DF, Schrier DJ, Sircar JC..  (1991)  Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors.,  34  (2): [PMID:1847426] [10.1021/jm00106a006]

Source

Source(1):

• Scientific Literature